The clean beat across all segments with record revenue and earnings supports the stock's momentum. Watch for any forward commentary on the upcoming earnings call regarding the impact of geopolitical/trade uncertainties on H2 demand. The expanded credit facility signals M&A optionality.
Price Chart
Executive Summary
Balchem Corp reported Q2 2026 results with net sales of $284.0M (+11.2% YoY) and GAAP EPS of $1.39 (+18.8% YoY), both exceeding consensus estimates. Adjusted EPS of $1.49 beat the $1.43 consensus by 4.2%. All three segments delivered record or near-record sales and earnings growth. The company also amended its credit facility, increasing borrowing capacity to $650M and extending maturity to 2031, and repurchased $29M of stock during the quarter. This is a clean beat across all key metrics with no offsetting negatives, though no explicit forward guidance was provided.
Key Financial Metrics
Key Facts
- Net sales of $284.0M, +11.2% YoY, record quarterly sales
- GAAP EPS of $1.39 vs $1.17 YoY, +18.8%
- Adjusted EPS of $1.49 vs consensus $1.43, a 4.2% beat
- Adjusted EBITDA of $77.9M, +12.6% YoY, a record
- All three segments (Human Nutrition, Animal Nutrition, Specialty Products) grew sales and earnings YoY
- Credit facility amended: increased to $650M, extended to 2031
- Repurchased $29M of common stock in Q2, $114M over trailing twelve months
- Net debt leverage ratio of 0.3x, very conservative balance sheet
Financial Impact
Q2 revenue $284.0M (+11.2% YoY), GAAP net earnings $44.6M (+16.6% YoY), adjusted EBITDA $77.9M (+12.6% YoY)
Risk Factors
- Geopolitical and global trade uncertainties cited by management could impact H2 performance
- Raw material cost inflation and higher operating expenses partially offset margin gains
- No explicit quantitative forward guidance provided, creating uncertainty on sustainability of growth rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000009326-26-000026 |
| Document: bcpc-20260731.htm | 0000009326-26-000026 |
| Document: 0000009326-26-000026-index-headers.html | 0000009326-26-000026 |
| Document: 0000009326-26-000026-index.html | 0000009326-26-000026 |
| Document: 0000009326-26-000026.txt | 0000009326-26-000026 |
| 8-K Data (Synthetic) | 0000009326-26-000026 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $175.49 | awaiting T+20 | — | $177.00 (+0.86%) |
Oct 23, 2026 3d ago | Press Release | $175.49 | awaiting T+20 | — | $177.00 (+0.86%) |
Jul 31, 2026 12w ago | 8-K | $167.56 $178.44 | ▲ +6.50% | ▲ +3.51% | $177.00 (+5.64%) |
Jul 31, 2026 12w ago | Press Release | $167.56 $178.44 | ▲ +6.50% | ▲ +3.51% | $177.00 (+5.64%) |
Jul 24, 2026 13w ago | 8-K | $164.79 $177.50 | ▲ +7.71% | ▲ +4.41% | $177.00 (+7.41%) |
Jul 17, 2026 14w ago | Press Release | $163.35 $178.51 | ▲ +9.28% | ▲ +4.83% | $177.00 (+8.36%) |
May 20, 2026 22w ago | Court Ruling | $161.75 $165.57 | ▲ +2.36% | ▲ +2.14% | $177.00 (+9.43%) |
Apr 16, 2026 27w ago | Press Release | $174.45 | awaiting T+20 | — | $177.00 (+1.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers